Richard Evan Sutton, MD, PhD
Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Chief, Infectious Diseases Research at VACTCards
Contact Info
About
Copy Link
Titles
Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Chief, Infectious Diseases Research at VACT
Biography
After finishing his undergraduate studies at Brown University, Dr. Sutton enrolled in the MSTP at Stanford, where he obtained his PhD degree with Dr. John Boothroyd, working on trans-splicing in African trypanosomes. He then completed a categorical residency in internal medicine at the Hospital of the University of Pennsylvania and a fellowship in infectious diseases at UCSF. After post-doctoral stints with Drs. Harold Varmus, Dan Littman, and Pat Brown in which he worked on HTLV cell binding and entry and the development of HIV-based gene therapy vectors, he joined the faculty at Baylor College of Medicine. In 2008 he was recruited to Yale to continue his work on HIV replication and lentiviral vectors. Dr. Sutton spends approximately 50% of his time at the research bench and 25% in the clinical setting, both out-patient and in-patient, mainly at the West Haven VA (VACT). He now the Chief of Infectious Diseases Research at VACT, which takes up roughly 25% of his time. Dr. Sutton was the Chief of Infectious Diseases at VACT from 2013-2024. Dr. Sutton took an administrative leave of absence in mid-April 2022, but he resumed all of his clinical, educational, and research activities before the beginning of 2023. The research focus of Dr. Sutton's laboratory is currently CCR5 transcriptional and post-transcriptional control and also novel anti-HIV therapeutics, specifically aimed at HIV Tat, Capsid, Nucleocapsid, Matrix, and Rev.
Appointments
Infectious Diseases
ProfessorPrimaryMicrobial Pathogenesis
ProfessorSecondary
Other Departments & Organizations
- Developmental Therapeutics
- Infectious Diseases
- Internal Medicine
- Microbial Pathogenesis
- Microbiology
- Molecular Cell Biology, Genetics and Development
- Virology Laboratories
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Stem Cell Center
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Post-doctoral fellow
- UCSF then Stanford University (1998)
- Fellow
- UC San Francisco (1993)
- Resident
- Hospital University of Pennsylvania (1992)
- PhD
- Stanford University School of Medicine (1989)
- MD
- Stanford University School of Medicine (1989)
Board Certifications
Infectious Disease
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2014
- Original Certification Date
- 1994
Research
Copy Link
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0001-7418-2378
Research at a Glance
Yale Co-Authors
Publications Timeline
Tassos C. Kyriakides, PhD
Publications
2025
I Died—and Was Brought Back to Life—Twice
Sutton R. I Died—and Was Brought Back to Life—Twice. Clinical Infectious Diseases 2025, ciaf612. PMID: 41363205, DOI: 10.1093/cid/ciaf612.Peer-Reviewed Original ResearchThe role of the 3′-UTR of the chemokine receptor CCR2 and hnRNPA0 in regulating mRNA stability and subcellular distribution in human CD4+ T cells
Yukselten Y, Wishah H, Wang L, Sutton R. The role of the 3′-UTR of the chemokine receptor CCR2 and hnRNPA0 in regulating mRNA stability and subcellular distribution in human CD4+ T cells. Frontiers In Immunology 2025, 16: 1655273. PMID: 40909274, PMCID: PMC12405378, DOI: 10.3389/fimmu.2025.1655273.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD4+ T cellsT cellsCCR2 mRNAPrimary CD4+ T cellsHuman CD4+ T cellsHIV co-receptorsChemokine receptor CCR2Immune cell migrationHIV infectionReceptor CCR2Chemokine receptorsCCR2 levelsCCR2MRNA stabilityCo-receptorProtein levelsRNA-binding proteinsChemokinesHIVHalf-lifeMRNAInfectious diseasesCCR2 activationGene expressionCell migration
2024
Targeting CCR5: A central approach to HIV treatment and cure strategies
Yukselten Y, Wishah H, Li J, Sutton R. Targeting CCR5: A central approach to HIV treatment and cure strategies. Virology 2024, 603: 110375. PMID: 39729963, DOI: 10.1016/j.virol.2024.110375.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMonoclonal antibody-based therapiesTherapeutic interventionsImmune-regulatory mechanismsAntibody-based therapiesEffective treatment strategiesCCR5 expressionHIV pathogenesisFunctional cureHIV infectionHIV entryT cellsCure strategiesCCR5HIV treatmentHomozygous mutationTreatment strategiesSmall molecule inhibitorsHIVCo-receptorViral entryGenetic variantsTherapyGene editing technologyHost cellsCure30 years of HIV therapy: Current and future antiviral drug targets
Nuwagaba J, Li J, Ngo B, Sutton R. 30 years of HIV therapy: Current and future antiviral drug targets. Virology 2024, 603: 110362. PMID: 39705895, PMCID: PMC11788039, DOI: 10.1016/j.virol.2024.110362.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsHIV-1HIV-1 cureCCR5 co-receptorInhibit HIV-1 replicationHIV-1 RNAHIV-1 replicationTarget reverse transcriptaseHIV-1 TatViral long terminal repeatFunctional cureAntiretroviral therapyHIV therapyNovel therapiesDrug resistanceLong terminal repeatDrug interactionsTherapeutic strategiesTherapeutic gapLifelong adherenceCo-receptorViral entryTherapyHAARTReverse transcriptaseDrugInvestigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes
Yukselten Y, Akang E, Wang L, Su P, Sutton R. Investigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes. Virology 2024, 603: 110341. PMID: 39642611, DOI: 10.1016/j.virol.2024.110341.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsEntry inhibitorsCombination antiviral therapyLow-dose combinationHIV entry inhibitorsHIV infectionHIV replicationAntiviral therapyAntiretroviral therapeuticsHIV treatmentTemsavirAntagonistic effectEffective treatmentHIVCD4EnfuvirtideMaravirocIbalizumabAntiviral strategiesInhibitorsTreatmentVariable responsesAntagonistic activityAntiretroviralsTherapyJAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells
Wang L, Yukselten Y, Nuwagaba J, Sutton R. JAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells. Science Advances 2024, 10: eadl0368. PMID: 38507500, PMCID: PMC10954213, DOI: 10.1126/sciadv.adl0368.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD4+ T cellsT cellsCCR5 expressionPrimary CD4+ T cellsCD4+ T cellsHuman CD4+ T cellsHuman primary CD4+ T cellsGlucocorticoid-regulated kinase 1HIV cure agendaHIV co-receptorsSignaling pathwayCCR5 levelsJAK/STAT inhibitor tofacitinibViremic patientsHIV patientsHIV infectionInhibitor tofacitinibJAK/STAT signaling pathwayCCR5Co-receptorHIVProtein levelsCCR2/CCR5Adverse effectsDown-regulation
2023
Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors
Slotkin R, Kyriakides T, Kundu A, Stack G, Sutton R, Gupta S. Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors. PLOS ONE 2023, 18: e0289713. PMID: 37643190, PMCID: PMC10464955, DOI: 10.1371/journal.pone.0289713.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2018
Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel
Kiros Y, Elinav H, Gebreyesus A, Gebremeskel H, Azar J, Chemtob D, Abreha H, Elbirt D, Shahar E, Chowers M, Turner D, Grossman Z, Haile A, Sutton R, Maayan S, Wolday D. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV Medicine 2018, 20: 33-37. PMID: 30318718, PMCID: PMC6510948, DOI: 10.1111/hiv.12680.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStable CD4 countsElite controllersCD4 countAntiretroviral treatmentIsraeli cohortAfrican cohortART-naïve subjectsHIV elite controllersLarge African cohortHIV-positive patientsUndetectable viral loadCells/μLWarrants further investigationEthiopian patientsViral loadOverall prevalenceCohortPatientsPrevalenceFirst cohortUnique subgroupPossible environmental factorsSignificant differencesHomogenous populationSelection biasCell-Intrinsic Immunity
Elinav H, Sutton R. Cell-Intrinsic Immunity. 2018, 231-240. DOI: 10.1007/978-1-4939-7101-5_270.Peer-Reviewed Original Research
2014
Cell-Intrinsic Immunity
Elinav H, Sutton R. Cell-Intrinsic Immunity. 2014, 1-11. DOI: 10.1007/978-1-4614-9610-6_270-1.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Mechanisms of HIV latency
HIC ID2000021845REGRoleSub InvestigatorPrimary Completion Date12/31/2048Recruiting ParticipantsGenderBothAge18+ yearsImpact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures
HIC ID1608018239RoleSub InvestigatorPrimary Completion Date09/01/2021Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Copy Link
Activities
activity NIH-NIAID & NIH-NIDA
07/01/2003 - PresentPeer Review Groups and Grant Study SectionsMemberDetailsStudy Sectionactivity Identifying and characterizing HIV+ elite and viremic controllers
07/01/2015 - 07/01/2018ResearchDetailsMek'ele, Tigray, EthiopiaAbstract/SynopsisWe have active collaborations with two sites in Africa to recruit HIV+ individuals who are able to control HIV in the absence of ART; we are actively exploring whether there is a genetic component to virologic control in these individuals.
activity Identifying Elite Controllers in Uganda
11/10/2017 - PresentResearchDetailsKampala, Central Region, Uganda
Honors
honor 2013 Avant Garde Scholar
07/01/2013National AwardNIH-NIDADetailsUnited Stateshonor Edward Mallinckrodt Jr. Foundation Scholar
07/01/2001National AwardEdward Mallinckrodt, Jr. Foundation (St. Louis, MO)DetailsUnited Stateshonor Pfizer Postdoctoral Scholar Award
07/01/1993National AwardPfizer Pharmaceutical CompanyDetailsUnited States
Get In Touch
Copy Link